{"id":46372,"date":"2022-07-20T14:01:52","date_gmt":"2022-07-20T12:01:52","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\/"},"modified":"2022-07-20T14:01:52","modified_gmt":"2022-07-20T12:01:52","slug":"nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\/","title":{"rendered":"Nanostics Announces the Launch of its Bladder Cancer Clinical Study to Identify the Most Potent Disease Predictors for Early Detection of Bladder Cancer"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nClinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America.\n<\/li>\n<li>\nThe aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics\u2019 ClarityDX\u00ae diagnostic platform.\n<\/li>\n<li>\nThe study is supported in part by the Alberta Innovates AICE-Concepts Program with a $600,000 award to Dr. John Lewis, Bird Dogs Chair in Translational Cancer Research at the University of Alberta.\n<\/li>\n<\/ul>\n<p>EDMONTON, Alberta&#8211;(BUSINESS WIRE)&#8211;Nanostics Inc., a precision health diagnostics company, is excited to launch a prospective clinical study designed to validate a novel and minimally invasive bladder cancer diagnostic test, ClarityDX Bladder, using its ClarityDX\u00ae diagnostic platform. In partnership with the University of Alberta\u2019s Alberta Prostate Cancer Research Initiative (APCaRI) and DynaLIFE Medical Labs, the study will recruit patients at sites in Alberta and Northern Ontario. Financial support for the study is provided with a $600,000 financial contribution through the Alberta Innovates AICE-Concepts Program. A preliminary 142-patient study with ClarityDX Bladder showed that it could accurately identify patients with bladder cancer compared to healthy individuals.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220720005204\/en\/1518563\/5\/Clarity_DX_BLADDER_Logo_2.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220720005204\/en\/1518563\/21\/Clarity_DX_BLADDER_Logo_2.jpg\"><\/a><\/p>\n<p>\nBladder cancer is the fifth most prevalent cancer in North America. Seventy percent of bladder cancer cases are low-grade, noninvasive, non-fatal, recurring tumors requiring life-long surveillance. The remaining 30% are high-grade, aggressive, fatal tumors requiring rapid and intensive treatment. Most bladder cancers are asymptomatic, making diagnosis and follow-up surveillance a significant challenge. Currently, bladder cancers are diagnosed using cystoscopy, the gold standard procedure for bladder cancer screening, and monitored with urine cytology tests. Cystoscopy is invasive, uncomfortable, and has limited detection capacity for some forms of bladder cancer.\n<\/p>\n<p>\nNanostics\u2019 ClarityDX Bladder test uses extracellular vesicle detection technology and machine-learning model analysis to identify the most potent disease predictors for the early detection of bladder cancer.\n<\/p>\n<p>\n\u201cStrategic investments in digital health are enabling Alberta to become more globally competitive towards increasing health and economic benefits for our province,\u201d says Sunil Rajput, Director of Research for Health Innovation with Alberta Innovates. \u201cOur<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Falbertainnovates.ca%2Fprograms%2Faccelerating-innovations-into-care-aice-concepts%2F&amp;esheet=52785946&amp;newsitemid=20220720005204&amp;lan=en-US&amp;anchor=AICE-Concepts+Program&amp;index=1&amp;md5=8b7fad177e9cbc980cabfa026167547f\" rel=\"nofollow noopener\" shape=\"rect\"> AICE-Concepts Program<\/a> is a strong example of digital health investments to power research towards addressing unmet clinical needs.\u201d\n<\/p>\n<p>\nImplementing ClarityDX Bladder as a highly accurate, noninvasive bladder cancer test will allow for straightforward diagnosis of low-grade bladder cancers and more rapid detection of aggressive bladder cancer before cystoscopy. This would transform bladder cancer care by making it easier to detect changes in tumor status without cystoscopy and improving active surveillance of bladder cancer patients.\n<\/p>\n<p>\n\u201cWe are excited to launch our bladder cancer study and thank all the patients for their generous participation in the study,\u201d John Lewis, CEO of Nanostics said, \u201cthe detection of early-stage bladder cancer is a critical first step for improving patient outcomes.\u201d\n<\/p>\n<p>\nRecently, Nanostics announced positive results from the clinical validation study of its lead prostate cancer diagnostic test, ClarityDX Prostate\u00ae, showing 94% sensitivity, 37% specificity, 49% positive predictive value, and 90% negative predictive value for predicting clinically significant (grade group \u22652) prostate cancer. Implementation could eliminate up to 37% of unnecessary biopsies and significantly reduce the number of unnecessary treatments for prostate cancer.\n<\/p>\n<p>\n<b>About Nanostics Inc.<\/b>\n<\/p>\n<p>\nNanostics is a private Alberta-based company focused on the development and commercialization of novel and noninvasive diagnostic tests. Its core technology, ClarityDX\u00ae, uses advanced machine learning algorithms to create a disease risk score. ClarityDX\u00ae is applicable to a wide range of cancers and other diseases. Nanostics\u2019 lead product, ClarityDX Prostate\u00ae, is a test that improves the accuracy of detecting clinically significant prostate cancer. Read more at: <b><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nanosticsdx.com&amp;esheet=52785946&amp;newsitemid=20220720005204&amp;lan=en-US&amp;anchor=www.nanosticsdx.com&amp;index=2&amp;md5=d13b25dd989828d5f07f8359894458c2\" rel=\"nofollow noopener\" shape=\"rect\">www.nanosticsdx.com<\/a>.<\/b>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Corporate Contact:<\/b><br \/>John Lewis, Ph.D.<br \/>\n<br \/>CEO, Nanostics, Inc.<br \/>\n<br \/><a target=\"_blank\" href=\"mail&#116;&#111;&#58;&#105;&#110;&#102;&#111;&#x40;&#x6e;&#x61;&#x6e;&#x6f;&#x73;&#x74;&#x69;&#x63;sdx&#46;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#x6e;&#x66;&#x6f;&#x40;&#x6e;&#x61;&#x6e;&#x6f;&#x73;&#x74;&#x69;&#x63;&#x73;&#x64;&#x78;&#x2e;&#x63;&#x6f;&#x6d;<\/a><\/p>\n<p><b>Media Contact:<\/b><br \/>Perrin Beatty<br \/>\n<br \/>+1-800-672-2027\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America. The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics\u2019 ClarityDX\u00ae diagnostic platform. The study is supported in part by the Alberta &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46372","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanostics Announces the Launch of its Bladder Cancer Clinical Study to Identify the Most Potent Disease Predictors for Early Detection of Bladder Cancer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanostics Announces the Launch of its Bladder Cancer Clinical Study to Identify the Most Potent Disease Predictors for Early Detection of Bladder Cancer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America. The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics\u2019 ClarityDX\u00ae diagnostic platform. The study is supported in part by the Alberta ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-20T12:01:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220720005204\/en\/1518563\/21\/Clarity_DX_BLADDER_Logo_2.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Nanostics Announces the Launch of its Bladder Cancer Clinical Study to Identify the Most Potent Disease Predictors for Early Detection of Bladder Cancer\",\"datePublished\":\"2022-07-20T12:01:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\\\/\"},\"wordCount\":618,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005204\\\/en\\\/1518563\\\/21\\\/Clarity_DX_BLADDER_Logo_2.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\\\/\",\"name\":\"Nanostics Announces the Launch of its Bladder Cancer Clinical Study to Identify the Most Potent Disease Predictors for Early Detection of Bladder Cancer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005204\\\/en\\\/1518563\\\/21\\\/Clarity_DX_BLADDER_Logo_2.jpg\",\"datePublished\":\"2022-07-20T12:01:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005204\\\/en\\\/1518563\\\/21\\\/Clarity_DX_BLADDER_Logo_2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005204\\\/en\\\/1518563\\\/21\\\/Clarity_DX_BLADDER_Logo_2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanostics Announces the Launch of its Bladder Cancer Clinical Study to Identify the Most Potent Disease Predictors for Early Detection of Bladder Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanostics Announces the Launch of its Bladder Cancer Clinical Study to Identify the Most Potent Disease Predictors for Early Detection of Bladder Cancer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Nanostics Announces the Launch of its Bladder Cancer Clinical Study to Identify the Most Potent Disease Predictors for Early Detection of Bladder Cancer - Pharma Trend","og_description":"Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America. The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics\u2019 ClarityDX\u00ae diagnostic platform. The study is supported in part by the Alberta ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-20T12:01:52+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220720005204\/en\/1518563\/21\/Clarity_DX_BLADDER_Logo_2.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Nanostics Announces the Launch of its Bladder Cancer Clinical Study to Identify the Most Potent Disease Predictors for Early Detection of Bladder Cancer","datePublished":"2022-07-20T12:01:52+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\/"},"wordCount":618,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220720005204\/en\/1518563\/21\/Clarity_DX_BLADDER_Logo_2.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\/","url":"https:\/\/pharma-trend.com\/en\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\/","name":"Nanostics Announces the Launch of its Bladder Cancer Clinical Study to Identify the Most Potent Disease Predictors for Early Detection of Bladder Cancer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220720005204\/en\/1518563\/21\/Clarity_DX_BLADDER_Logo_2.jpg","datePublished":"2022-07-20T12:01:52+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220720005204\/en\/1518563\/21\/Clarity_DX_BLADDER_Logo_2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220720005204\/en\/1518563\/21\/Clarity_DX_BLADDER_Logo_2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/nanostics-announces-the-launch-of-its-bladder-cancer-clinical-study-to-identify-the-most-potent-disease-predictors-for-early-detection-of-bladder-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Nanostics Announces the Launch of its Bladder Cancer Clinical Study to Identify the Most Potent Disease Predictors for Early Detection of Bladder Cancer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46372","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46372"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46372\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46372"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46372"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46372"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}